| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies | Company's Home Page |
| Array BioPharma Inc. |
| 1885 33rd Street, Boulder, CO 80301 * (303) 381-6600 |
| Business Description | Array BioPharma is a discovery research company creating drug candidates through innovations in chemistry. |
| Offering Information Company has | |||
| Trading As | ARRY (NASNTL) | Industry | Not Classified |
| Type of Stock Offered | Common Shares | Filing Date | 9/15/00 |
| Domestic Shares Offered | 6,500,000 | Offer Date | 11/16/00 |
| Foreign Shares Offered | 0 | Filing Range | $8.00 - $9.00 |
| Company Shares | 6,500,000 | Offer Price | $7.50 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.525 |
| Gross Proceeds | $48,750,000 | Selling | $0.315 |
| Expenses | $800,000 | Reallowance | $0.100 |
| Post-IPO Shares | 21,404,332 | Employees | 100 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| Deutsch Banc Alex. Brown | Co-manager | (410) 727-1700 |
| Legg Mason Wood Walker, Inc. | Co-manager | (410) 539-4038 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 6/30/98 | 6/30/99 | 6/30/00 | ||||
| Revenues | - | - | 0.000 | 1.503 | 6.773 | - | - |
| Income from Oper. | - | - | -0.063 | -4.352 | -4.702 | - | - |
| Net Income | - | - | -0.049 | -4.307 | -4.730 | - | - |
| E.P.S | - | - | - | - | -0.400 | - | - |
| Revenue Growth (%) | - | - | - | 350.632 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -1.34 | - | - | ||||
| Cash Flow - Inv. | -7.08 | - | - | ||||
| Cash Flow - Fin. | 10.08 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 15.82 | Current Assets | 8.55 | Current Ratio | 1.35 |
| Total Liab. | 9.17 | Current Liab. | 6.34 | Debt Ratio | 57.96% |
| Total Equity | 6.65 | Working Cap. | 2.21 | Debt to Equity Ratio | 1.38 |
| Cash | 3.85 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund our operations, including continued development and manufacturing of existing products as well as research and development of additional products and services, hire additional personnel and expand our facilities to be able to meet the growing needs of our business. We also may use a portion of the net proceeds to acquire or invest in new products, businesses or technologies and pay down our indebtedness. We intend to use the balance of the net proceeds for general corporate purposes, including working capital. Our management may spend the proceeds from this offering in ways that the stockholders may not deem desirable. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Hogan & Hartson |
| Bank's Law Firm | Latham & Watkins |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| ARCH Venture Fund III, L.P. | 15.00 | 10.80 |
| Frazier Healthcare II, L.P. | 13.80 | 9.90 |
| Falcon Technology Partners L.P. | 11.50 | 8.30 |
| Boulder Ventures II, L.P. | 11.50 | 8.30 |
| Rovent II Limited Partnership | 6.00 | 4.30 |
| Note: represents ownership of 5% or more prior to the offering. | ||